Статья

COVID-19 in cystic fibrosis patients

E. Kondrat’eva, S. Krasovskiy, N. Kashirskaya, E. Amelina, E. Zhekayte, V. Sherman, O. Simonova, Y. Gorinova, E. Boitsova, M. Mukhina, I. Butyugina, M. Makarova, A. Malakhov,
2020

Since the beginning of the COVID-19 epidemic, the European cystic fibrosis society (ECFS) has decided to launch a special ECFS-COVID-19 program to collect information on the of COVID-19 characteristics in the patients with cystic fibrosis (CF). The results of the program should help timely and efficiently provide the patients with CF with the necessary care. Initially, it was assumed that COVID-19 would be severe in CF patients. The aim. Тo assess the prevalence and characteristics of COVID-19 in patients with cystic fibrosis (CF) in the Russian Federation (RF). Methods. 6 cases (4 children and 2 adults) of COVID-19 in Russian CF patients were analyzed. Results. There are 405,843 infected with SARS-CoV-2 in Russia, the incidence of coronavirus infection in Russia was 1.4 cases per 1 thousand people. According to the Ministry of Health of the RF, as of December 2019, there were 3,931 patients with CF (2,823 children and 1,108 adults). The incidence of COVID-19 was 1.5 per 1000 patients with CF (1.4: 1,000 for children and 1.8: 1,000 for adults). The incidence was not higher than in the General population. The diagnosis of COVID-19 was confirmed in 4 boys and 2 women, 3 of the patients were infected with Pseudomonas aeruginosa and 2 – with Achromobacter spp. Mild disease was seen in 5 patients including all the children. Pneumonia was registered in 3 patients. One child with COVID-19 had abdominal syndrome. 2 patients – 1 adult and 1 child – needed in-patient care. Additional antibiotics were given to 4 patients, 2 of them received i/v antibiotics. One adult patient was on the lung transplantation waiting list. This woman had long-term oxygen therapy and BiPAP noninvasive respiratory support before the infection with SARS-CoV-2, FEV was 24 % Conclusion. Despite the fact that patients with CF are at risk of severe COVID-19, to date, in the described cases, COVID-19 infection has not led to a significant deterioration of the symptoms of CF. Not a single fatal outcome in Russian patients with CF has been recorded. 1 pred.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2020-01-01

Метаданные

Об авторах
  • E. Kondrat’eva
    Russian Academy of Sciences
  • S. Krasovskiy
    Russian Academy of Sciences, Federal Medical and Biological Agency of Russia
  • N. Kashirskaya
    Russian Academy of Sciences
  • E. Amelina
    Federal Medical and Biological Agency of Russia
  • E. Zhekayte
    Russian Academy of Sciences
  • V. Sherman
    Russian Academy of Sciences
  • O. Simonova
    Healthcare Ministry of Russia, Moscow Healthcare Department, Sechenov First Moscow State Medical University
  • Y. Gorinova
    Healthcare Ministry of Russia
  • E. Boitsova
    Saint Petersburg State Pediatric Medical University
  • M. Mukhina
    Moscow Healthcare Department
  • I. Butyugina
    Federal Medical and Biological Agency of Russia
  • M. Makarova
    Pirogov Russian National Research Medical University (RNRMU)
  • A. Malakhov
    Sechenov First Moscow State Medical University
Название журнала
  • Pulmonologiya
Том
  • 30
Выпуск
  • 5
Страницы
  • 544-552
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus